RT @ericdeinmd: #ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE 335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO
Tweet Content
#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE
335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO
83% SRI4 response in TEL vs 38% PBO (p<0.001)
As early as w4, sustained to w52
Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI
@RheumNow #ACRBest https://t.co/UpEwEaonDO
Show on Archive Page
On
Display in Search Results
On
PDQ
Off